


Speaker's Profiles



Professor Dr David Banta

David Banta, often referred to as the "Father of HTA", received his MD degree from Duke University and MPH and MS degrees from Harvard University School of Public Health. In 1975 he joined the U.S. Congressional Office of Technology Assessment, where he headed a team that laid out the basic definitions and principles of the then-new field of health technology assessment (HTA).

In 1983 he began a long-term relationship with the World Health Organization (WHO), working on the staff in Washington and Copenhagen, and later consulting with WHO staff and traveling to different countries under WHO auspices. During these years, he developed a strong interest in HTA in developing countries. In 1993, he joined the Netherlands Applied Research Organization (TNO), where he worked on issues related to HTA in the Netherlands, in Europe, and in many countries around the world. At the same time, he is Professor Emeritus at Maastricht University, where he taught

HTA and supervised several doctoral candidates. He has consulted many times with the World Bank, working on HTA in China and Malaysia, and in a number of Eastern European countries. He has also often been a consultant to national and regional governments or their HTA programs. He has published extensively on issues related to HTA and policies toward health technology.



Dr Ellen FM t'Hoën

Ellen t'Hoën is a lawyer and public health advocate with over 30 years of experience working on pharmaceutical and intellectual property policies. She works as an independent consultant in medicines law and policy for a number of international organisations and governments and is a researcher at the Global Health Unit of the University Medical Center Groningen, The Netherlands.

From 1999 until 2009 she was the Director of Policy and Advocacy at Médecins sans Frontières' (MSF) Campaign for Access to Essential Medicines. In 2009 she joined UNITAID to set up the [Medicines Patent Pool](#) (MPP), an initiative that negotiates patent licenses to ensure access to affordable generic medicines. She was the MPP's first executive director until 2012.

She is a member of the [Lancet Commission on Essential Medicines Policies](#), the Advisory Board of Universities Allied for Essential Medicines (UAEM) and the Editorial Board of the Journal of Public Health Policy. In 2005, 2006, 2010 and 2011 she was listed as one of the 50 most influential people in intellectual property by the journal *Managing Intellectual Property*. She has published widely and is the author of several books. In 2017 she received the [Prix Prescrire](#) for her latest book ["Private Patents and Public Health: Changing intellectual property rules for public health."](#)



Associate Professor Sivalal Sadasivan

Dr Sivalal Sadasivan is currently an Associate Professor at Jeffrey Cheah School of Medicine & Health Sciences, Monash University Malaysia, having joined the University in 2006. Dr Sivalal was previously the Head of the Health Technology Assessment Unit, and a Deputy Director of the Medical Development Division, Ministry of Health, Malaysia. He was also Director of the WHO Collaborating Centre for Evidence Based Practice in Health Care. Apart from managing the Health Technology Assessment programme in Ministry of Health Malaysia, he was also involved clinical practice guidelines, medical device regulation, hospital management, health care financing, and Quality Assurance.

He has been a consultant on health technology assessment in Turkey, Pakistan, Indonesia, and Iran, and a consultant with the World Health Organization on assisting Sudan with developing a national health technology policy, and later in setting up a system of medical device regulation.

In addition, he has presented innumerable papers at national and international conferences both locally and abroad, has had publications in numerous journals, and is an editor and reviewer for a number of international journals.



Dr Junainah Sabirin

Dr Junainah Sabirin is a Public Health Physician, who graduated from University of Malaya, Malaysia (MBBS and MPH).

She heads the Malaysian Health Technology Assessment Section (MaHTAS), as a Deputy Director of Medical Development Division, Ministry of Health, Malaysia. She has been working in MaHTAS for the last 10 years and has been involved in conducting health technology assessment especially for facilities under the Ministry of Health, Malaysia. She is currently responsible for the implementation HTA activities including local economic evaluation, Horizon Scanning activities, Evidence-based Clinical Practice Guidelines development and implementation, Value Based Medicine and related training.

Dr Junainah has previously worked in hospitals, district health offices and at the Disease Control Division, Ministry of Health, Malaysia.



Mr Jean-Michel Piedagnel

Jean-Michel Piedagnel graduated from École de Commerce (ESCE), an international business school in Paris. He started his career working for the world's largest sailing boat manufacturer in sales, marketing and export manager in France.

In 1995, he joined Médecins Sans Frontières to run some of their most challenging relief projects, in DRC, Goma, Burundi, Nigeria, Kosovo, Lebanon, Sierra Leone, Angola and Pakistan. After working in the headquarters in Paris, he moved to London as the Executive Director for seven years and oversaw a period of unprecedented growth and enhanced reputation for MSF in the UK. Under his leadership, MSF UK was voted to be the most Admired British Charity in 2004 and 2005. He joined Drugs for Neglected Diseases Initiative (DNDi) as Head of the South-East Asia office, in April 2016.

Ms Chee Yoke Ling



Ms Chee Yoke Ling is an international lawyer whose areas of expertise include the environmental, social and economic impacts of globalization, especially in countries of the South. Since 1993 she has worked closely with key negotiators from the global South, scientists and NGOs to campaign for bio safety and climate justice. She was a member of a Malaysian task force that worked on two national laws related to bio safety and the regulation of access to genetic resources. Her current focus areas are: climate change, the interface between biodiversity/traditional knowledge and intellectual property rights, the relationship between multilateral environmental agreements and trade agreements, environmentally-sound technology transfer, and developments on these issues at the UN Framework Convention on Climate Change, Convention on Biological Diversity, World Trade Organisation, and the World Intellectual Property Organisation. She is a Director of Third World Network, a non-profit international policy research and advocacy organization involved in sustainable development issues. She is trained in international law, with degrees from the University of Malaya (Malaysia) and Cambridge University (UK).